Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Centocor Inc.

(CNTO)

UBS Securities analyst David Crossen lowered his

ReoPro

sales estimates for 1995 to $50 million from $60 million,

Read the full 222 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE